Mass Screening of Prostate Cancer and its Impact on Inhabitants in Akita Prefecture, Japan

Abstract

In 2001, the Akita Medical Association started a prostate cancer (PC) mass screening project for ≥ 50-year-old male inhabitants in individual ­municipalities of Akita Prefecture, utilizing serum prostate-specific antigen. The number of examinees increased from 4321 in 2001 to 29 936 in 2006, while the annual rate of examinees per target inhabitants remained at 11.6 to 16.8 % and the fraction of repeat examinees ­increased up to 77 % in 2006. A total of 944 PCs were screened with a stage B tumor incidence of 84.1 % (range: 82.2 to 86.6 %). The annual PC detection rate was 0.95 to 1.11 % for the first 4 years, but then declined to 0.54 % in 2006 mainly due to the increase of repeat examinees. PSA mass screening is effective for the detection of early stage PC, but a further promotion is needed to mobilize the sleeping inhabitants. Indeed, the number of new PC patients in 17 major hospitals in Akita Prefecture rapidly increased after the mass screening started (3.2-fold), suggesting an enlightenment effect of the screening project on both the inhabitants and general physicians.

Key words

prostate cancer - mass screening - Akita Prefecture - Japan

References

• 1 Japanese Ministry of Health, Welfare and Labor .Report on 2006 Population Statistics of Japan.  http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai06/index.html
• 2 Hsing A W, Tsao L, Devesa S S. International trends and patterns of prostate cancer incidence and mortality.  Int J Cancer. 2000;  85 60-67
• 3 Shiraishi T, Ioshii S O, Watanabe H et al. Geographic pathology of latent prostatic carcinoma: an international comparison. In: Imai K, Shima­zaki J, Karr JP, eds. Fundamental Approaches to the Diagnosis and Treatment of Prostate Cancer and BPH. New York: Adenine Press, Schenectady; 1994: 21–25
• 4 Kuroishi T, Hirose K, Tominaga Y et al. Prediction of cancer mortality in Japan. In: Oshima A, Kuroishi T, Tajima K, eds. Cancer Statistics Report 2004. Tokyo: Shinohara Shuppan; 2004: 221–234 (in Japanese)
• 5 Labrie F, Candas B, Cusan L et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial.  Prostate. 2004;  59 311-318
• 6 Catalona W J, Loeb S, Han M. Viewpoint: expanding prostate cancer screening.  Ann Intern Med. 2006;  144 441-443
• 7 Oberaigner W, Horninger W, Klocker H et al. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing.  Am J Epidemiol. 2006;  164 376-384
• 8 Lu-Yao G, Albertsen C A, Stanford J L et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut.  Br Med J. 2002;  325 740-745
• 9 Concato J, Wells C K, Horwitz R I et al. The effectiveness of screening for prostate cancer: a nested case-control study.  Arch Intern Med. 2006;  166 38-43
• 10 Schroeder F H, Denis L J, Roobol M. all participants of the ERSPC . The story of the European randomized study of screening for prostate cancer.  Br J Urol Int. 2003;  92 (suppl 2) 1-13
• 11 Andriole G, Levin D L, Crawford E D et al. Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial.  J Nat Cancer Inst. 2005;  97 433-438
• 12 Barry M J. The PSA conundrum (editorial).  Arch Intern Med. 2006;  166 7-8